LYDIA GREBE: Open Payments
NPI 1780788729 · COLUMBUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,369 in 78 payments from 18 companies in 2025. Trend: 2023 $781 · 2024 $1,429 · 2025 $1,369
Food & beverage: $1,369
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $303 |
| ABBVIE INC. | 23 | $256 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Astellas Pharma US Inc | 4 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $72 |
| Lilly USA, LLC | 4 | $71 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $65 |
| AstraZeneca Pharmaceuticals LP | 4 | $63 |
| Lundbeck LLC | 3 | $56 |
| Amgen Inc. | 3 | $50 |
Products named: VRAYLAR, Ozempic, REXULTI, Veozah, CAPLYTA, MOUNJARO, Kerendia, AIRSUPRA.
Industry payments across NJ — which companies pay providers there.
